REPL

Replimune Group (REPL)

About Replimune Group (REPL)

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Details

Daily high

$4.18

Daily low

$3.30

Price at open

$3.32

52 Week High

$13.24

52 Week Low

$1.50

Market cap

275.8M

Dividend yield

0.00%

Volume

15.1M

Avg. volume

11.3M

P/E ratio

-.93

Replimune Group News